At the time of writing, Ultragenyx Pharmaceutical Inc. [RARE] stock is trading at $56.33, up 1.09%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The RARE shares have gain 0.37% over the last week, with a monthly amount glided 10.67%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Ultragenyx Pharmaceutical Inc. [NASDAQ: RARE] stock has seen the most recent analyst activity on June 06, 2024, when Goldman upgraded its rating to a Buy and also boosted its price target to $67 from $56. Previously, RBC Capital Mkts started tracking the stock with Outperform rating on April 22, 2024, and set its price target to $77. On December 08, 2023, Wells Fargo initiated with a Overweight rating and assigned a price target of $72 on the stock. Evercore ISI upgraded its rating to a Outperform and raised its price target to $80 on June 06, 2023. Cantor Fitzgerald started tracking with a Overweight rating for this stock on April 26, 2023, and assigned it a price target of $114.
For the past year, the stock price of Ultragenyx Pharmaceutical Inc. fluctuated between $31.52 and $58.73. Currently, Wall Street analysts expect the stock to reach $108.14 within the next 12 months. Ultragenyx Pharmaceutical Inc. [NASDAQ: RARE] shares were valued at $56.33 at the most recent close of the market. An investor can expect a potential return of 91.98% based on the average RARE price forecast.
Analyzing the RARE fundamentals
According to Ultragenyx Pharmaceutical Inc. [NASDAQ:RARE], the company’s sales were 481.30M for trailing twelve months, which represents an 35.75% jump. Gross Profit Margin for this corporation currently stands at 0.83% with Operating Profit Margin at -1.14%, Pretax Profit Margin comes in at -1.22%, and Net Profit Margin reading is -1.22%. To continue investigating profitability, this company’s Return on Assets is posted at -0.36, Equity is -2.66 and Total Capital is -0.41. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of2.08.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 55.33 points at the first support level, and at 54.34 for the second support level. However, for the 1st resistance point, the stock is sitting at 56.93, and for the 2nd resistance point, it is at 57.54.
Ratios To Look Out For
It is important to note that Ultragenyx Pharmaceutical Inc. [NASDAQ:RARE] has a current ratio of 3.54. In addition, the Quick Ratio stands at 3.39 and the Cash Ratio stands at 1.78. Considering the valuation of this stock, the price to sales ratio is 10.79, the price to book ratio is 11.99.
Transactions by insiders
Recent insider trading involved KAKKIS EMIL D, President & CEO, that happened on Sep 03 ’24 when 20000.0 shares were sold. SVP, Chief Accounting Officer, Huizenga Theodore Alan completed a deal on Sep 03 ’24 to sell 91.0 shares. Meanwhile, Officer KAKKIS EMIL D bought 20000.0 shares on Sep 03 ’24.
